Erise IP logo

Erise Secures IPR for Client at PTAB

Erise shareholders Adam Seitz and Paul Hart, along with associate Cliff Brazen, successfully petitioned the Patent Trial and Appeal Board (PTAB) for inter partes review (IPR) on behalf of a technology client in a database patent infringement case against an intellectual property licensing company. The Erise team argued that 42 claims of the plaintiff’s patent […]

Erise Secures Federal Circuit Win

Erise shareholders Adam Seitz and Paul Hart were successful at the U.S. Court of Appeals for the Federal Circuit Federal Circuit on behalf of a technology client in a patent infringement case centering on a method for transmitting “signals from a plurality of transmission antennas.” After hearing oral arguments, the three-judge panel affirmed an April 2020 decision by the […]

Erise Continues PTAB Success at Managing IP Awards

The IP Boutique Has Made the Exclusive Shortlist Second Year in a Row Erise is pleased to announce it has maintained its place on the Managing Intellectual Property annual awards’ shortlist, making Erise one of the few firms to be nominated in the same category two consecutive years, and the only Kansas City-based law firm on either […]

Law360 Names Erise a “Go-To” PTAB Firm

Erise is pleased to announce it has been recognized as one of the top 20 elite national firms for its work at the Patent Trial and Appeal Board (PTAB) in 2020 by Law360. Ranked 16th, Erise is the only firm of its size to be listed among other BigLaw firms with multiple offices and thousands of attorneys. Indeed, […]

Adam Seitz Named to Managing IP Awards Shortlist

Erise is pleased to announce shareholder Adam Seitz was named to the Managing Intellectual Property Awards’ shortlist, where he’s honored as a nationwide Patent Trial and Appeal Board (PTAB) Practitioner of the Year. The winner will be announced April 7 at a virtual awards ceremony. The short list was compiled by Managing IP after obtaining information from thousands of firms, […]

Law360 recognizes Erise IP’s efforts to help overturn Fintiv at the PTAB

The Patent Trial and Appeal Board is considering a request it received sent by Erise IP shareholder Adam Seitz on behalf of Garmin, Law360 reported. In the request, Garmin is asking the PTAB’s Precedential Opinion Panel “to hold that the timing of U.S. International Trade Commission investigations shouldn’t be used to deny parallel patent challenges, especially […]

Erise IP Recognized as a Top 50 PTAB Law Firm by Patexia Insights

Erise IP was recognized by Patexia, the world’s largest network for intellectual property professionals, in the fourth annual IPR Intelligence Report 2020 for being one of the top 50 best performing law firms at the Patent Trial and Appeal Board (PTAB). Over a five-year period between July 1, 2015 to June 30, 2020, Patexia evaluated 915 […]

PTAB Issues Final Written Decision in Favor of Erise IP

Erise IP is pleased to announce the Patent Trial and Appeal Board issued a final written decision on behalf Unified Patents, holding that all but one dependent claim of a non-practicing entity’s patent is unpatentable. Led by shareholders Jason Mudd and Eric Buresh, Erise IP filed the IPR a year ago on a patent that is “directed […]

Erise IP Secures IPR Non-Institution on the Merits

Defending patent owner Gracenote, Erise IP shareholders Jennifer Bailey, Jason Mudd, Megan Redmond and senior associate Robin Snader recently obtained a merits-based non-institution for three IPRs filed by the petitioner, Free Stream Media (d/b/a Samba). The U.S. Patent Trial and Appeal Board (PTAB) deemed Samba failed to demonstrate a reasonable likelihood of prevailing at trial […]

Erise Victorious at the PTAB

Erise IP shareholders Adam Seitz and Paul Hart scored another win at the Patent Trial and Appeal Board when the panel invalidated claims after Erise “persuasively demonstrated that a skilled artisan would have been motivated to combine elements of several prior art references – earlier patents and printed publications – to arrive at the patent owner’s claimed invention,” […]

Skip to content